Adenovirus infection results in alterations of insulin signaling and glucose homeostasis.
Recombinant adenovirus (Ad) vectors can initiate an inflammatory response, limiting its use in gene therapy and basic research. Despite increased efforts to better understand Ad infection, little is known about how it affects cellular metabolic responses. In the current studies, we explored the effects of Ad vectors on insulin signaling molecules and glucose homeostasis. Nonreplicative Ad vectors were injected into rats through the tail vein, and at 4-13 days postinjection insulin signaling and glucose tolerance were examined. Ad vector infection significantly reduced total levels of the insulin receptor (IR), and insulin receptor substrates 1 and 2 (IRS-1, IRS-2) in the liver of rats, resulting in decreased insulin-induced tyrosine phosphorylation of IR, IRS-1, and IRS-2, and decreased interaction of IRS-1 and IRS-2 with phosphoinositide 3-kinase (PI3K). In addition, Ad infection resulted in impaired systemic glucose homeostasis, which recovered by 13 days, after the protein levels of IR, IRS-1, and IRS-2 had started to normalize. Expression of a TNF inhibitor or Kupffer cell depletion attenuated the Ad vector-induced decreases of insulin signaling molecules, indicating a potential role of Kupffer cell activation in this process. These studies provide evidence that systemic administration of Ad vectors can impair insulin signaling in liver, resulting in altered systemic glucose metabolism. Thus, effects of Ad vector infection on insulin action and glucose metabolism need to be considered when Ad vectors are used in research or gene therapy and may be more broadly applicable to other viral agents.
Jiang
Shaoning
S
Department of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.
Gavrikova
Tatyana A
TA
Pereboev
Alexander
A
Messina
Joseph L
JL
D000256:Adenoviridae / Q000378:metabolism*; D000257:Adenoviridae Infections / Q000378:metabolism* / Q000821:virology; D000818:Animals; D015153:Blotting, Western; D005822:Genetic Vectors; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D007150:Immunohistochemistry; D007328:Insulin / Q000378:metabolism*; D055504:Insulin Receptor Substrate Proteins / Q000378:metabolism; D007728:Kupffer Cells; D008099:Liver / Q000201:enzymology / Q000378:metabolism / Q000821:virology; D008297:Male; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011972:Receptor, Insulin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; C526296:Irs1 protein, rat; D014409:Tumor Necrosis Factor-alpha; D019869:Phosphatidylinositol 3-Kinases; D011972:Receptor, Insulin; D005947:Glucose
J Virol. 1997 Jan;71(1):624-9
8985392
Hepatology. 2003 Dec;38(6):1384-92
14647049
Nat Rev Genet. 2003 May;4(5):346-58
12728277
J Virol. 1997 Nov;71(11):8798-807
9343240
Hepatology. 2008 Jun;47(6):2127-33
18446789
Curr Opin Mol Ther. 2008 Oct;10(5):439-48
18830919
J Leukoc Biol. 1992 Sep;52(3):296-302
1522388
Diabetes. 2003 Sep;52(9):2239-48
12941762
Hum Gene Ther. 2004 Dec;15(12):1157-66
15684693
Am J Pathol. 2004 Nov;165(5):1499-508
15509521
Mol Ther. 2001 May;3(5 Pt 1):697-707
11356075
Science. 1996 Feb 2;271(5249):665-8
8571133
Hum Gene Ther. 1999 Apr 10;10(6):965-76
10223730
Am J Gastroenterol. 2009 Jan;104(1):76-82
19098853
Acta Physiol (Oxf). 2008 Jan;192(1):29-36
18171427
J Gastroenterol Hepatol. 2008 May;23(5):779-82
18028349
FEBS Lett. 2008 Jan 9;582(1):97-105
18053812
Endocrinology. 2004 Nov;145(11):5168-76
15297437
Science. 1999 Dec 17;286(5448):2244-5
10636774
Trends Endocrinol Metab. 2006 Mar;17(2):72-8
16458527
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):215-9
8278368
J Biol Chem. 2008 Dec 19;283(51):35375-82
18952604
Int J Obes (Lond). 2005 Jun;29(6):603-6
15738934
Intern Emerg Med. 2008 Jun;3(2):99-108
18274709
J Cell Sci. 2006 Sep 15;119(Pt 18):3788-98
16940353
N Engl J Med. 1996 May 2;334(18):1185-7
8602187
Endocrinology. 2009 Jan;150(1):24-32
18801909
Gene Ther. 2000 Jun;7(12):1034-8
10871752
Endocrinology. 1998 Dec;139(12):4928-35
9832430
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1200-5
9037030
Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96
16493415
Oncologist. 2002;7(1):46-59
11854546
J Biol Chem. 2002 Nov 1;277(44):42394-8
12228220
Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G107-15
12388175
J Nutr. 2001 Oct;131(10):2794S-2797S
11584109
Am J Gastroenterol. 2003 Dec;98(12):2751-6
14687828
J Gen Virol. 1997 Jul;78 ( Pt 7):1527-31
9225025
Hum Gene Ther. 2003 May 1;14(7):627-43
12804145
Mol Cell. 2000 Jul;6(1):87-97
10949030
J Biol Chem. 2004 Oct 29;279(44):45803-9
15331609
Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S46-8
14704744
Gene Ther. 2003 Jun;10(11):935-40
12756413
Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E581-91
18728222
Endocrinology. 2008 May;149(5):2369-82
18187553
J Virol. 2004 May;78(10):5368-81
15113916
Hum Gene Ther. 2003 Nov 20;14(17):1631-41
14633405
Endocrinology. 2007 Jun;148(6):2994-3003
17379643
Am J Physiol Endocrinol Metab. 2002 Sep;283(3):E413-22
12169433